ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer

NEXT STORY
TELEFLEX ANNOUNCES FIRST QUARTER 2020 EARNINGS CONFERENCE CALL INFORMATION
PREV STORY
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement

author_avatar
NASDAQ Market News

Asterias Biotherapeutics Announces Facilities and IP License Option Agreements

Transactions Provide Additional Cash to Advance Clinical Programs and Process Development while Reducing Fixed ...

author_avatar
NASDAQ Market News

United States Companion Animal Diagnostics Market Outlook and Forecast 2018-2023: Growing Demand for Automated Analyzers and Integration of Various Diagnostic Platforms

Dublin, Dec. 19, 2018 (GLOBE NEWSWIRE) -- The "Companion Animal Diagnostics Market in US ...

author_avatar
NASDAQ Market News